Vedolizumab for the Treatment of Active Ulcerative Colitis: A Randomized Controlled Phase 2 Dose-ranging Study
Asit Parikh, Brian G. Feagan(Western University), Catherine Scholz(Kura Oncology (United States)), Serap Sankoh(Millennium Engineering and Integration (United States)), Diane R. Mould(Phoenixville Hospital), Tim Wyant(Curis (United States)), Irving H. Fox(Takeda (United States)), Timothy Leach(Takeda (United States)), Terry Ponich(London Health Sciences Centre)
Cited by 211
Related Papers
Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2005|3.9k
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2013|2.9k
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
|New England Journal of Medicine|2013|2.7k
Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target
|The American Journal of Gastroenterology|2015|1.8k
Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease
|New England Journal of Medicine|2016|1.8k